ISRCTN13334317 https://doi.org/10.1186/ISRCTN13334317

Evaluation of a new and simple diagnostic test for malaria

Submission date
19/01/2022

Recruitment status
No longer recruiting

Registration date
22/02/2022

Overall study status
Completed

Last Edited
17/10/2023

Condition category
Infections and Infestations

[_] Prospectively registered
[X] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol

Background and study aims
Malaria is the most important parasitic disease worldwide. The disease is caused by the malaria parasite which dwells in the blood of infected patients. It is important to find out if a case is infected as immediate treatment with the right drugs is important to circumvent death or severe disease. Current tests (diagnostic tests, like microscopy or rapid diagnostic tests) to detect the malaria parasite in blood have limitations. They may not be sensitive enough (do not detect the parasite; they are “false negative”) or remain positive after successful treatment (“false positive”). A molecular diagnostic test based on the detection of parasite genetic material (DNA) might be much better, but their use in resource-limited countries (like many countries in Africa), because they require sophisticated equipment and a constant supply of electricity.
Our project has developed a simple molecular diagnostic test that circumvents difficult DNA extractions (it is directly on blood), requires simple equipment (mini PCR machine), runs on solar power, and has a simple dipstick readout system. In the current project, we want to explore how well these new tests can detect malaria parasites in blood compared to currently available systems. The work is done in 5 African countries (Sudan, Ethiopia, Burkina Faso, Kenya, and Namibia) that all face problems with malaria diagnosis.

Who can participate?
Persons living in the catchment areas of the health centres of the participating study institutes with the suspicion of malaria (male/female, all ages) can participate in the study.

What does the study involve?
Persons who participate in the study are suspected of having malaria and attend a health facility. In addition to blood samples that will be taken from them in the context of routine diagnosis, we will take an additional small blood sample for experimental testing. Furthermore, we will take some additional clinical and demographic data. The outcome of experimental testing will not be used for the clinical management of study cases. The patients will be treated and managed according to the national health guidelines for malaria.

What are the possible benefits and risks of participating?
Cases will not have to pay the service fee for their clinic visit during this study. This study will

help us to learn how the new diagnostic test will work best in patients. This may help to provide (potential) malaria patients with a better diagnosis in the future.
The risks to the safety of participants in the study is negligible as we will not provide any experimental drug. In addition, our new test will not influence the care the doctor will provide to cases and treatment will be based on the results of the health facility's usual tests. The only risk we see could be that related to the blood collection. Indeed, the risks of drawing blood from a finger prick include temporary discomfort from the needle stick, bruising, skin infection, and fainting. However, the amount of blood collected is too small to affect participants'', and any discomfort will rapidly go away.

Where is the study run from?
Academic Medical Center (Netherlands)

When is the study starting and how long is it expected to run for?
March 2019 to November 2024

Who is funding the study?
European and Developing Countries Clinical Trials Partnership

Who is the main contact?
Dr Henk Schallig, h.d.schallig@amsterdamumc.nl

Contact information

Type(s)
Principal investigator

Contact name
Dr Henk Schallig

ORCID ID
https://orcid.org/0000-0002-7096-6279

Contact details
Amsterdam University Medical Centers
Academic Medical Center at the University of Amsterdam
Department of Medical Microbiology and Infection Prevention
Laboratory for Experimental Parasitology
Amsterdam
Netherlands
1105AZ
+31 646285524
h.d.schallig@amsterdamumc.nl

Additional identifiers

Clinical Trials Information System (CTIS)
Nil known

Protocol serial number

PACTR202202766889963

Study information

Scientific Title
Phase 3 evaluation of an innovative simple molecular test for the diagnosis of malaria in different endemic and health settings in sub-Saharan Africa

Acronym
DIAGMAL

Study objectives
The diagnostic performance of the mini-dbPCR-NALFIA test for malaria (investigational product) has a better diagnostic performance than current diagnsotic practises in place in the particpating study sites

Ethics approval required
Old ethics approval format

Ethics approval(s)
1. Approved 07/04/2021, Ethics committee of the University of Gezira, Faculty of Medicine (P.O. Box 20 Wad Medani, Sudan; +249912320250; saeedosman82@yahoo.com), ref: n/a
2. Approved 10/03/2021, National ethical committee for research (03 BP7009 Ouagadougou, Burkina Faso; +226 25 33 35 94; kouetafla@yahoo.com), ref: 2021-03-057
3. Approved 01/04/2021, Institutional ethical committee in health sciences (Comité d'Ethique Institutionnel pour la Recherche en Science de la Santé, Centre National de la Recherche Scientifique et Technologique, Direction Régionale Ouest, 01 BP 545 Bobo-Dioualsso 01, Burkina Faso; +226 20981880; rouama_noelw@yahoo.fr), ref: N/Réf. A02-2021/CEIRES
4. Approved 30/06/2021, Department research ethics review committee (DRERC) of the department of microbiology, Immunology and Parasitology (DMIP) (Addis Ababa University, Addis Ababa, Ethiopia; no telephone number provided; abelishasweet@yahoo.com), ref: DRDRC /04/2021
5. Approved 25/11/2021, Ministry of Education (National Ethics Review Committee; Ministry of Education, Addis Ababa, Ethiopia; no telephone number provided; daniel.tadesse@ethernet.edu.et), ref: 7/1-61/m259/35
6. Approved 07/09/2021, Institutional Review Board of the Addis Ababa University, College of Health Science (Addis Ababa, Ethiopia; no telephone number provided; adamuaddissie@gmail.com), ref: 07/2021
7. Approved 01/07/2021, Amref Ethics and Scientific Review Committee (P.O. Box 30125, 00100 Nairobi, Kenya; +254.20.6994000; esrc.kenya@amref.org), ref: AMREF – ESRC P991/2021
8. Approved 12/04/2021, Ministry of Health and Social Services (Harvey Street Private Bag, 13198 Windhoek, Namibia; +264.61.203.2507; Shipanga@mhss.gov.na), ref: 17/3/3/DRM

Study design
Phase 3 diagnostic trial

Primary study design
Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied
Malaria (uncomplicated Plasmodium falciparum malaria)

Interventions
Comparison of different diagnostic tests for malaria.

Diagnostic performance will be assessed following the WHO/TDR guidelines for the evaluation of diagnostics and the results will be reported according to STARD principles. This phase 3 evaluation will be a prospective multi-centre diagnostic study on populations living in different malaria endemic settings and for which the disease status of each individual is not previously known. Study participants (all ages) will be identified during their visits at the study health facilities. Subjects (or parent or legal guardian in case of minors) suspected of having malaria will be asked to participate in the diagnostic study.

Next to a blood sample collected for routine diagnosis in place for malaria, from each eligible case a blood sample (finger prick) will be collected in an sample (EDTA) tube for analysis with the test under investigation. An additional sample will be collected on filter paper for further comparison and quality control with PCR in reference laboratory. Some basic clinical and demographic data will be collected too. After sample collection the patients will be further referred to the local clinical practise in place. The result of experimental testing will not be taken into account whilst managing the patient. There will be no active follow-up of cases. The total duration of participation is estimated to be between 10 and 60 minutes.

Intervention Type
Device

Phase
Phase III

Drug/device/biological/vaccine name(s)
Not applicable

Primary outcome(s)
Diagnostic accuracy measured as sensitivity, specificity, negative and positive predictive value of index test (dbPCR-NALFIA) compared to reference (standard) tests at point of diagnostic testing (enrolment of study case)

Key secondary outcome(s))
1. To determine the direct and indirect costs and benefits of allocating limited resources to implement the mini-dbPCR-NALFIA test for malaria compared to current diagnostic strategies in place. Descriptive outcome measured as availability of a report at the end of the trial
2. To determine potential barriers to successfully implement the new diagnostic platform within local, socio-economic and cultural contexts under routine conditions. Descriptive outcome measured as availability of a report at the end of the trial
3. To build a draft product dossier for CE marking and pre-qualification and to identify potential producers that can bring the platform to the market (exploitation objective). Effectiveness of dossier drafting is measured by the availability of a draft product dossier at the end of the trial
4. To strengthen the capacity of all five African partners in the field of diagnostic clinical trials, including Good Clinical and Laboratory Practices (GC/LP) training of research and auxiliary staff

and prospective MSc/ PhD students, and to improve the research infrastructure at the trial sites. Effectiveness of capacity building is measured as number of staff trained at the end of the trial.
5. To disseminate the outcomes of the project to stakeholders, including scientific peers, diagnostic entities, policy makers and the lay public. Effectiveness of dissemination is measured as number of publications in peer reviewed journals at the end of the trial

Completion date
30/11/2024

Eligibility

Key inclusion criteria
In Sudan, Ethiopia, Burkina Faso and Kenya, the study will include patients who fulfil the following inclusion criteria:
1. Potential participant (patients with clinical suspicion of malaria) of all ages presenting at the health facility;
2. Coming from the health centre catchment area;
3. Informed consent from patient or of parents/guardians (in case of minors).
In Namibia, the study will include persons who fulfil the following criteria:
1. Be a resident of one of the selected households or have slept the night before in this household.
2. Informed consent from potential participants (individually).

Participant type(s)
Other

Healthy volunteers allowed
No

Age group
All

Sex
All

Total final enrolment
4541

Key exclusion criteria
Not meeting the above inclusion criteria, depending on study site.

Date of first enrolment
01/12/2021

Date of final enrolment
31/05/2024

Locations

Countries of recruitment

Burkina Faso

Ethiopia

Kenya

Namibia

Sudan

Study participating centre
Institut de Recherche en Sciences de la Santé (IRSS)
Clinical Research Unit of Nanoro (CRUN)
Nanoro
Burkina Faso
BP 218 Ouaga CMS 11

Study participating centre
Blue Nile National Institute for Communicable Diseases
University of Gezira
Wad Medani
Sudan
01

Study participating centre
Amref Health Africa Headquarters
Wilson Airport
Nairobi
Kenya
01

Study participating centre
Addis Ababa University
Department of Microbiology, Immunology and Parasitology, College of Health Sciences,
Addis Ababa
Ethiopia
01

Study participating centre
University of Namibia
Multidisciplinary Research Center
Windhoek

Namibia
01

Sponsor information

Organisation
Academic Medical Center

ROR
https://ror.org/03t4gr691

Funder(s)

Funder type
Government

Funder Name
European and Developing Countries Clinical Trials Partnership

Alternative Name(s)
Le partenariat Europe-Pays en développement pour les essais cliniques, A Parceria entre a Europa e os Países em Desenvolvimento para a Realização de Ensaios Clínicos, The European & Developing Countries Clinical Trials Partnership (EDCTP), The European & Developing Countries Clinical Trials Partnership, European and Developing Countries Clinical Trials, EDCTP

Funding Body Type
Private sector organisation

Funding Body Subtype
International organizations

Location
Netherlands

Results and Publications

Individual participant data (IPD) sharing plan
All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary
Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		01/09/2022	02/09/2022	Yes	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes